中国食品药品网讯（记者落楠） 11月10日，第七届中国国际进口博览会（以下简称进博会）在上海落下帷幕。进博会药品板块集中布局7.2馆，汇聚十余家世界500强制药企业，今年企业带来的展品有哪些新看点？

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of HIV research findings at the International ...

We need nothing less than disruptive action to ensure everyone who wants access to affordable lenacapavir can get it.

Despite a robust HIV portfolio and growing oncology sales, Gilead struggles to diversify revenue streams significantly. Learn ...

Lenacapavir (previously GS-6207) is the first in a new class of class HIV-1 capsid inhibitor that Gilead is hoping will eventually free patients from the need to take daily oral tablets, although ...

He expressed optimism that this growth will continue, driven by the potential approval of lenacapavir as a preventive ...

1. In this randomized controlled trial, among adolescent girls and young women, it was found that twice-yearly lenacapavir resulted in a significantly reduced human immunodeficiency virus (HIV) ...

First, on 20 June 2024, came the results of the Purpose-1 trial in South Africa and Uganda.1 This randomised controlled trial found that twice yearly injection of the drug lenacapavir for pre-exposure ...

“我们已经是第三次参加进博会了，过去几年借助进博会的平台，我们既能够分享我们的研发成果及业务进展，同时也在加速我们的创新产品在中国上市，尽早惠及更多群体。最后，我们也通过进博会的平台开展了多方合作，与各类伙伴签约，从而加速我们在中国发展的进程。”第七 ...

Along with these most recent study results, the potent antiviral activities, and pharmacokinetic profiles of islatravir and lenacapavir support their continued development as an investigational ...